Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

6,284 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?
Caldwell GW, Masucci JA, Yan Z, Hageman W. Caldwell GW, et al. Among authors: yan z. Eur J Drug Metab Pharmacokinet. 2004 Apr-Jun;29(2):133-43. doi: 10.1007/BF03190588. Eur J Drug Metab Pharmacokinet. 2004. PMID: 15230342
ADME optimization and toxicity assessment in early- and late-phase drug discovery.
Caldwell GW, Yan Z, Tang W, Dasgupta M, Hasting B. Caldwell GW, et al. Among authors: yan z. Curr Top Med Chem. 2009;9(11):965-80. doi: 10.2174/156802609789630929. Curr Top Med Chem. 2009. PMID: 19747120 Review.
Screening for reactive intermediates and toxicity assessment in drug discovery.
Caldwell GW, Yan Z. Caldwell GW, et al. Among authors: yan z. Curr Opin Drug Discov Devel. 2006 Jan;9(1):47-60. Curr Opin Drug Discov Devel. 2006. PMID: 16445117 Review.
Bioactivation of 4-methylphenol (p-cresol) via cytochrome P450-mediated aromatic oxidation in human liver microsomes.
Yan Z, Zhong HM, Maher N, Torres R, Leo GC, Caldwell GW, Huebert N. Yan Z, et al. Drug Metab Dispos. 2005 Dec;33(12):1867-76. doi: 10.1124/dmd.105.006387. Epub 2005 Sep 20. Drug Metab Dispos. 2005. PMID: 16174805
Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides.
Yan Z, Li J, Huebert N, Caldwell GW, Du Y, Zhong H. Yan Z, et al. Drug Metab Dispos. 2005 Jun;33(6):706-13. doi: 10.1124/dmd.104.003095. Epub 2005 Mar 11. Drug Metab Dispos. 2005. PMID: 15764717
A high-throughput monoamine oxidase inhibition assay using liquid chromatography with tandem mass spectrometry.
Yan Z, Caldwell GW, Zhao B, Reitz AB. Yan Z, et al. Rapid Commun Mass Spectrom. 2004;18(8):834-40. doi: 10.1002/rcm.1415. Rapid Commun Mass Spectrom. 2004. PMID: 15095350
N-glucuronidation of the platelet-derived growth factor receptor tyrosine kinase inhibitor 6,7-(dimethoxy-2,4-dihydroindeno[1,2-C]pyrazol-3-yl)-(3-fluoro-phenyl)-amine by human UDP-glucuronosyltransferases.
Yan Z, Caldwell GW, Gauthier D, Leo GC, Mei J, Ho CY, Jones WJ, Masucci JA, Tuman RW, Galemmo RA Jr, Johnson DL. Yan Z, et al. Drug Metab Dispos. 2006 May;34(5):748-55. doi: 10.1124/dmd.106.009274. Epub 2006 Feb 2. Drug Metab Dispos. 2006. PMID: 16455802
Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses.
Yan Z, Rafferty B, Caldwell GW, Masucci JA. Yan Z, et al. Eur J Drug Metab Pharmacokinet. 2002 Oct-Dec;27(4):281-7. doi: 10.1007/BF03192339. Eur J Drug Metab Pharmacokinet. 2002. PMID: 12587958
Metabolic assessment in liver microsomes by co-activating cytochrome P450s and UDP-glycosyltransferases.
Yan Z, Caldwell GW. Yan Z, et al. Eur J Drug Metab Pharmacokinet. 2003 Jul-Sep;28(3):223-32. doi: 10.1007/BF03190489. Eur J Drug Metab Pharmacokinet. 2003. PMID: 14527096
The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
Caldwell GW, Ritchie DM, Masucci JA, Hageman W, Yan Z. Caldwell GW, et al. Among authors: yan z. Curr Top Med Chem. 2001 Nov;1(5):353-66. doi: 10.2174/1568026013394949. Curr Top Med Chem. 2001. PMID: 11899102 Review.
6,284 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback